- Home
- ZEO vs AKTX Comparison
ZEO vs AKTX Comparison
Compare ZEO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- AKTX
- Stock Information
- Founded
- ZEO 2005
- AKTX N/A
- Country
- ZEO United States
- AKTX United States
- Employees
- ZEO N/A
- AKTX N/A
- Industry
- ZEO
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- AKTX Health Care
- Exchange
- ZEO NYSE
- AKTX Nasdaq
- Market Cap
- ZEO 55.5M
- AKTX 41.8M
- IPO Year
- ZEO N/A
- AKTX N/A
- Fundamental
- Price
- ZEO $3.02
- AKTX $1.17
- Analyst Decision
- ZEO
- AKTX
- Analyst Count
- ZEO 0
- AKTX 0
- Target Price
- ZEO N/A
- AKTX N/A
- AVG Volume (30 Days)
- ZEO 170.4K
- AKTX 28.8K
- Earning Date
- ZEO 06-16-2025
- AKTX 08-18-2025
- Dividend Yield
- ZEO N/A
- AKTX N/A
- EPS Growth
- ZEO N/A
- AKTX N/A
- EPS
- ZEO N/A
- AKTX N/A
- Revenue
- ZEO $61,885,622.00
- AKTX N/A
- Revenue This Year
- ZEO N/A
- AKTX N/A
- Revenue Next Year
- ZEO N/A
- AKTX N/A
- P/E Ratio
- ZEO N/A
- AKTX N/A
- Revenue Growth
- ZEO N/A
- AKTX N/A
- 52 Week Low
- ZEO $1.05
- AKTX $0.85
- 52 Week High
- ZEO $4.75
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ZEO 55.75
- AKTX 44.98
- Support Level
- ZEO $2.77
- AKTX $1.15
- Resistance Level
- ZEO $3.25
- AKTX $1.22
- Average True Range (ATR)
- ZEO 0.44
- AKTX 0.08
- MACD
- ZEO -0.06
- AKTX -0.00
- Stochastic Oscillator
- ZEO 52.86
- AKTX 40.86
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy-efficient equipment, and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.